Viral Vectors and Plasmid DNA Manufacturing Market to Reach US$ 9 BN by 2027

The global Viral Vectors and Plasmid DNA Manufacturing market gathered revenue around USD 2.9 Billion in 2020 and to reach USD 9.0 Billion by 2027 and estimated to expand at a modest CAGR of 19.1% during the prediction period 2021 to 2027.

Growth Factors:

Along with the ongoing shift in the treatment paradigm of several life-threatening diseases through advanced therapies, there is rising demand for viral vector-based vaccines for infectious diseases. This has resulted in increasing employment of viral vectors and plasmid DNA for the R&D of advanced therapies, thereby driving the market for viral vectors and plasmid DNA manufacturing.

Amidst the COVID-19 pandemic, the demand for viral vectors has rapidly increased especially in vaccinology. This led to expanding manufacturing capabilities by operating players to meet the growing demand. The application of these vectors in vaccine development has witnessed significant growth in 2020.

Get the sample copy of report@ https://www.novaoneadvisor.com/report/sample/6029

Also, an increase in the number of gene therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive the demand for scalable production of gene therapy vectors. Owing to this, several private and public agencies are providing funds to accelerate advancements in the manufacturing processes for viral vectors.

Besides, the implementation of single-use technology can lead to significant savings in capital, operating costs, materials, and labor. The use of this equipment will enhance efficiency and improve flexibility, leading to high yields of the final product. Thus, advancements in single-use technology directly impact revenue growth in this space.

This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Viral Vectors And Plasmid DNA Manufacturing market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Viral Vectors And Plasmid DNA Manufacturing market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.

Highlights of the Report:

• Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market

Ask here for customization@ https://www.novaoneadvisor.com/report/customization/6029

Regional analysis:

North America dominated the viral vectors and plasmid DNA manufacturing market and accounted for the largest revenue share of 49.2% in 2020. The presence of a substantial number of centers and institutes that are engaged in the R&D of advanced therapies is one of the key contributing factors for the dominance of the region. With the increasing regulatory approvals for advanced therapies, the U.S. significantly contributed to the regional revenue generation.

In addition, U.S.-based companies are investing a significant amount to expand their manufacturing capabilities. For instance, in January 2021, Thermo Fisher Scientific acquired the viral vector manufacturing business of Groupe Novasep SAS (Novasep). This acquisition aimed at the expansion of the company’s CDMO service offerings. On the other hand, Asia Pacific is projected to witness the fastest growth rate throughout the forecast period.

Over the past several years, the Asian cell and gene therapy market has gained momentum in terms of product approvals and pipeline programs. This can be attributed to the establishment of accelerated approval pathways, growing private and government investments, and increasing healthcare needs. Besides, the unmet needs in the personalized medicine arena are driving the research for regenerative medicine, leading to increasing demand for viral vector supply.

Some of the prominent players in the Viral Vectors And Plasmid DNA Manufacturing Market include: Merck KGaA; Lonza; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; Cobra Biologics Ltd.; Thermo Fisher Scientific, Inc.; Waisman Biomanufacturing; Genezen; YPOSKESI; Advanced BioScience Laboratories, Inc. (ABL, Inc.); Novasep Holding S.A.S; Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.); Vigene Biosciences, Inc.; General Electric Company (GE Healthcare); CEVEC Pharmaceuticals GmbH; Batavia Biosciences B.V.; Biovion Oy; Wuxi AppTec Co., Ltd.; VGXI, Inc.; Catalent Inc.; Miltenyi Biotec GmbH; SIRION Biotech GmbH; Virovek Incorporation; BioNTech IMFS GmbH; VIVEbiotech S.L

Segments Covered in the Report

By Vector Type

• • Adeno associated virus (AAV)
  • Lentivirus
  • Adenovirus
  • Retrovirus
  • Plasmid DNA
  • Others

By Workflow

• • Upstream Processing
    • Vector Amplification & Expansion
    • Vector Recovery/Harvesting
  • Downstream Processing
    • Purification
    • Fill Finish

By Application

• • Antisense & RNAi
  • Gene Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

By End-Use

• • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

By Disease Outlook

• • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

Click Here to View Full Report Table of Contents

Buy this Research Report@ https://www.novaoneadvisor.com/report/checkout/6029

You can place an order or ask any questions, please feel free to contact at sales@novaoneadvisor.com | +1 9197 992 333